Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays.

• Tác giả: Jack G Anderson, Aleah Bowie, Jose F Cardona, Patrick Dennis, Valentine Ebuh, Steven A Geller, Maria D Iglesias-Ussel, Manish Jain, Yin Li, Mark M McKenzie, Kian Merchant-Borna, Lawrence P Park, Anand Patel, Amy Siegel, Guy S Strauss, Joby J Thoppil, Aaron S Weinberg, Christopher W Woods
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Microbiology spectrum , 2025
• Bộ sưu tập: NCBI
• ID: 54824

Tóm tắt

UNLABELLED: Timely diagnosis of SARS-CoV-2 is important for infection control and treatment. Real-time reverse transcriptase PCR (rRT-PCR) tests are the reference standard for diagnosis but often require a centralized laboratory, making them time-intensive and unsuitable for resource-limited settings. The Abbott ID NOW™ COVID-19 2.0 assay is a rapid point-of-care (POC), isothermal molecular test for qualitative detection of SARS-CoV-2. We prospectively evaluated its clinical performance against three reference rRT-PCR tests: Hologic Panther Fusion, Roche Cobas, and CDC 2019-nCoV RT-PCR Diagnostic Panel. Investigators enrolled 3,530 subjects, with 3,146 evaluable. In symptomatic subjects ( IMPORTANCE: The Abbott ID NOW